Caleb Roberts, VP Global Business Development at Antaros Medical, will present at the 9th Annual MASH Drug Development Summit on the role of advanced imaging in understanding disease progression and supporting drug development for metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). His talk ‘From Steatosis to Fibrosis and Beyond – What non-invasive Imaging Can Do in MASLD/MASH’ will examine how imaging biomarkers can provide critical insights to guide decision-making in clinical trials.
MASLD and its progressive form, MASH, are highly prevalent and often underdiagnosed, with fibrosis being the main predictor of poor outcomes. While lifestyle modification was long the only option, the approval of the first therapy in 2024 and the rapid expansion of late-stage drug candidates mark a turning point in treatment. Further, recent biomarker advances in this field aim to replace invasive biopsies with non-invasive tools, including imaging. Advanced MRI-based techniques such as proton density fat fraction (MRI-PDFF) for liver fat, magnetic resonance elastography (MRE) for stiffness are increasingly integrated into clinical trials and enable more efficient development strategies.
In his talk, Caleb will discuss the complexity of MASLD/MASH, its strong metabolic links to obesity, diabetes, and cardiovascular risk, and how advanced imaging can illuminate disease burden and progression. He will discuss how non-invasive imaging biomarkers—such as MRI-PDFF, MRE, and emerging PET techniques—are transforming clinical trials, alongside the integration of body composition and other imaging measurements of metabolically linked organs. Finally, he will talk about how insights from multiple biomarkers can shape and accelerate decision-making in drug development.
Join us for Caleb’s presentation at the MASH Drug Development Summit on Tuesday 30 September @ 3.15 pm EDT. The MASH Drug Development Summit takes place from 29 September – 1 October in Boston, MA.